These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37840379)

  • 21. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
    Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
    J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
    Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
    Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.
    Wang J; Xu-Monette ZY; Jabbar KJ; Shen Q; Manyam GC; Tzankov A; Visco C; Wang J; Montes-Moreno S; Dybkær K; Tam W; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Ferreri AJM; Wang S; Møller MB; Piris MA; Medeiros LJ; Li Y; Pham LV; Young KH
    Am J Pathol; 2017 Aug; 187(8):1700-1716. PubMed ID: 28627414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding of
    Zhang Y; Hu B; Li Y; Deng T; Xu Y; Lei J; Zhou J
    Autophagy; 2020 Sep; 16(9):1697-1710. PubMed ID: 31885313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
    Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ
    Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 28. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.
    Abramson JS; Chen W; Juszczynski P; Takahashi H; Neuberg D; Kutok JL; Takeyama K; Shipp MA
    Br J Haematol; 2009 Feb; 144(3):358-66. PubMed ID: 19036086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
    Smith PG; Wang F; Wilkinson KN; Savage KJ; Klein U; Neuberg DS; Bollag G; Shipp MA; Aguiar RC
    Blood; 2005 Jan; 105(1):308-16. PubMed ID: 15331441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possible involvement of the Hedgehog and PDPK1-Akt pathways in the growth and migration of small-cell lung cancer.
    Tang N; Hu B; Zhang Y; Chen Z; Yu R
    J Int Med Res; 2021 May; 49(5):3000605211016562. PubMed ID: 34038205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.
    Matsumura-Kimoto Y; Tsukamoto T; Shimura Y; Chinen Y; Tanba K; Kuwahara-Ota S; Fujibayashi Y; Nishiyama D; Isa R; Yamaguchi J; Kawaji-Kanayama Y; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
    Cancer Med; 2020 Jul; 9(14):5185-5199. PubMed ID: 32420699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.
    Bhalla S; Evens AM; Dai B; Prachand S; Gordon LI; Gartenhaus RB
    Blood; 2011 Jul; 118(4):1052-61. PubMed ID: 21628402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. POU2F2 regulates glycolytic reprogramming and glioblastoma progression via PDPK1-dependent activation of PI3K/AKT/mTOR pathway.
    Yang R; Wang M; Zhang G; Li Y; Wang L; Cui H
    Cell Death Dis; 2021 Apr; 12(5):433. PubMed ID: 33931589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma.
    Yousefi Z; Sharifzadeh S; Zare F; Eskandari N
    Mol Biol Rep; 2023 Feb; 50(2):1133-1145. PubMed ID: 36409389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
    Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L
    Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
    Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
    Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR‑16‑2‑3p inhibits cell proliferation and migration and induces apoptosis by targeting PDPK1 in maxillary primordium mesenchymal cells.
    Han T; Wu N; Wang Y; Shen W; Zou J
    Int J Mol Med; 2019 Mar; 43(3):1441-1451. PubMed ID: 30664182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
    Chen E; Pei R
    J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.